The information on this page is updated via a feed from the London Stock Exchange's Regulatory News Service.
FORM 6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report of Foreign
Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the Securities
Exchange Act of 1934
For 26 August
2009
Commission File
Number: 001-11960
AstraZeneca
PLC
15 Stanhope Gate,
London W1K 1LN, England
Indicate by check
mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If
“Yes” is marked, indicate below the file number assigned to the Registrant in
connection with Rule 12g3-2(b): 82-_____________
AstraZeneca
PLC
INDEX TO
EXHIBITS
1.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4”, dated 26 August
2009.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
AstraZeneca
PLC
Date: 2
September 2009
By:
/s/ Justin
Hoskins
Name:
Justin
Hoskins
Title:
Deputy
Company Secretary
Item 1
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 25 August 2009 the interest of Lynn Tetrault, a person discharging
managerial responsibilities, in AstraZeneca American Depositary Shares (ADSs)
has changed as detailed below. One ADS equals one Ordinary Share. The
change in interest relates to the vesting of an award made in August under the
AstraZeneca Executive Performance Share Plan, whereby, following the application
of performance measures specified at the time of grant, Lynn Tetrault has now
become beneficially entitled to a percentage of the shares originally
awarded. In accordance with the plan rules, the unvested part of the
award has immediately and irrevocably lapsed. In addition, sufficient
vested shares were withheld to cover certain tax obligations arising on the
vesting.
Name
Number of
Shares Awarded
Vesting
Percentage
Number of
Shares Lapsed
Number of
Shares Vested
Number of
Shares Withheld
Net Number of
Shares
Lynn
Tetrault
1,522
75%
380
1,142
371
771
The closing market
price of AstraZeneca ADSs on 24 August 2009 was $46.16.
A
C N Kemp
Company
Secretary
26
August 2009
